PLAY PODCASTS
Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
Season 1 · Episode 8

Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

Master One Thing - Rapamycin Longevity Series

January 17, 20241h 22m

Audio is streamed directly from the publisher (masteronething.se) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Dr Joan Mannick is one of the world’s leading rapamycin and mTOR researchers in the longevity field. Joan has a background in academic medicine and is currently CEO at her own company Tornado Therapeutics where they focus on developing the next generation of mTOR inhibitors. One of the company goals is to create a mTOR inhibitor which is better than Rapamycin. Throughout the years Joan has made important discoveries in humans when it comes to finding a connection between mTOR inhibition and improvement of the aging immune system. In this podcast we are going to talk about her research, drug development, mTOR, rapamycin, rapalogs and other interesting longevity topics.

Links

https://www.tornado-tx.com

Joan's LinkedIn

Joan’s research publications

Big thanks to TimePie for the research help for this episode

Rapamycin resources

Rapamycin.news

Rapamycin Facebook group

Rapamycin Reddit group

Connect with Krister on:

Twitter

LinkedIn

Instagram

Disclaimer: The podcast is for general information and educational purposes only and is not medical advice for you or others. The use of information and materials linked to the podcast is at the users own risk. Always consult your physician with anything you do regarding your health or medical condition.